HP
CHRS icon

Hound Partners’s Coherus Oncology CHRS Stock Holding History

Hound Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-665,444
Closed -$10.8M – 56
2020
Q1 		$10.8M Sell
665,444
-440,429
-40% -$8.14M 1.01% 20
2019
Q4 		$19.9M Hold
1,105,873
– – 1.38% 16
2019
Q3 		$22.4M Sell
1,105,873
-474,154
-30% -$9.47M 1.43% 19
2019
Q2 		$34.9M Sell
1,580,027
-379,291
-19% -$6.59M 1.7% 17
2019
Q1 		$26.7M Sell
1,959,318
-57,509
-3% -$767K 1.15% 21
2018
Q4 		$18.3M Buy
2,016,827
+6,551
+0.3% +$75.8K 0.59% 21
2018
Q3 		$33.2M Buy
2,010,276
+1,231,768
+158% +$21.8M 0.77% 18
2018
Q2 		$10.9M Buy
+778,508
New +$11.1M 0.26% 19

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Hound Partners's CHRS Position: Q2 2020 in Review

Hound Partners sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 665,444 shares — an estimated $10.8M sold.

Hound Partners first reported a position in CHRS in Q2 2018 and held it in 8 quarters. The position peaked at $34.9M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • Hound Partners reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • Hound Partners sold 665,444 Coherus Oncology shares in Q2 2020, an estimated $10.8M.
  • Hound Partners first reported a position in Coherus Oncology in Q2 2018 and held it in 8 quarters.
  • Hound Partners's Coherus Oncology position peaked at $34.9M in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Hound Partners's 13F filing for Q2 2020, filed 14 Aug 2020.